SI-BONE, Inc. (SIBN)
Nasdaq · Healthcare · Medical Devices
$19.81+9.57%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $888M
- 52-week range
- $11.48 – $21.89
- 52-week change
- +17.94%
- EPS (trailing)
- −$0.34
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 9, 2026
Fiscal year to Dec 2025
- Revenue
- $201M (+20.19%)
- Net income
- −$18.9M
- Operating margin
- −11.1%
- Diluted EPS
- −$0.44
- Free cash flow
- −$9.1M
From the company’s annual report on SEC EDGAR.
About SI-BONE, Inc.
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium implant with a triangular cross-section and porous surface that stabilizes the joint and facilitates the biological fixation of the bone onto the implant to drive fusion; IFUSE 3D, a triangular titanium implant with a porous surface and fenestrated design to self-harvest bone; IFUSE BONE, which supports and augments the patient's own bone tissue in orthopedic procedures; IFUSE TORQ, an additively-manufactured threaded implant designed to allow for osteointegration, or incorporation of the bone into the implant's porous surface and structure; IFUSE BEDROCK GRANITE, an implant with a machined titanium core and a tulip that attaches to the rod and provides fusion and fixation to the sacroiliac joint as a foundational element for segmental spinal fusion; and IFUSE TORQ TNT, a porous threaded…
Headquarters: Santa Clara, United States · 376 employees · si-bone.com